Histogenics Corp., a regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products primarily for orthopedic tissue repair, today announced the appointment of Peter Greenleaf to Chief Executive Officer.
Bringing over 20 years of experience in the biotechnology industry to Histogenics, Mr. Greenleaf most recently served as President of MedImmune, the worldwide biologics arm of AstraZeneca. During his tenure, he presided over the expansion of MedImmune’s extensive growth and pipeline and spearheaded industry-leading business development and venture deals. Mr. Greenleaf also served as the President of MedImmune Ventures, overseeing more than $300 million in investments in early stage portfolio companies. Prior to becoming President, Greenleaf led the development of the company’s global marketing and portfolio organizations and managed the broader commercial, corporate development and strategy functions.